Objectives To evaluate the QoL considering the personality structure, the levels of anxiety and health conditions in patients with cystic fibrosis after LT. Methods The SF36 – QoL questionnaire ...(scale 0–100) and the STAI-Y test were administered during the follow-up after LT. Results 13 subjects (6 males) with cystic fibrosis were assessed. The mean value of SF36 was 86.0 points (in females 87.8 and in males 83.8 points). Surprisingly, the STAI-Y 1 test showed higher levels of state anxiety compared to reference values in 100% of males and 71.4% of females. In the same way, the STAI-Y 2 test, which assesses the trait of anxiety in the personality, showed a high score in 76.8% of subjects. It occurred in all males and 57% of females. The mean value of FEV1 was 81.2 (±20.01). Conclusions Although the QoL and the lung function showed values in the normal range, but the level of anxiety was very high in our patients. One possible reason could be that QoL is strongly related to physical performance. Health workers should anyway consider the coexistence of both a good QoL and a high level of anxiety after LT. So it is necessary to plan a systematic psychological support for the transplanted patients even where they give us a good construction of their life.
We describe a statistical method to estimate the composition of a sample of particle tracks in terms of the species of these particles. We consider the case when the particle identification ...information strongly depends on some kinematical variables, whose distributions are poorly known and different for each particle species. We show that the proposed procedure provides a properly normalized estimate of the unknown distributions with minimal assumption on their functional form. Moreover, we show that the method can be generalized to any kinematical distribution of the particles.
Individuals with chronic diseases and parent caregivers are at increased risk for symptoms of depression and anxiety. Prevalence of psychological symptoms was evaluated in adolescents and adults with ...cystic fibrosis (CF) and parent caregivers across nine countries.
Patients with CF, ages 12 years and older, and caregivers of children with CF, birth to18 years of age, completed measures of depression and anxiety across 154 CF centres in Europe and the USA. Psychological symptoms were compared across countries using χ(2). Logistic regression examined extent of comorbid symptoms, predictors of depression and anxiety, and concordance between parent and adolescent symptomatology.
Psychological symptoms were reported by 6088 patients with CF and 4102 parents. Elevated symptoms of depression were found in 10% of adolescents, 19% of adults, 37% of mothers and 31% of fathers. Elevations in anxiety were found in 22% of adolescents, 32% of adults, 48% of mothers and 36% of fathers. Overall, elevations were 2-3 times those of community samples. Participants reporting elevated anxiety were more likely to report depression (ORs: adolescents=14.97, adults=13.64, mothers=15.52, fathers=9.20). Significant differences in reports of depression and anxiety were found by patient age and parent respondent. Concordance between 1122 parent-teen dyads indicated that adolescents whose parents reported depression were more likely to be elevated on depression (OR=2.32). Similarly, adolescents whose parents reported anxiety were more likely to score in the elevated range on the anxiety measure (OR=2.22).
Symptoms of depression and anxiety were elevated in both patients with CF and parents across several European countries and the USA. Annual screening of psychological symptoms is recommended for both patients and parents.
Abstract The inclusion of health-related quality of life (HRQoL) as an outcome measure in cystic fibrosis (CF) clinical trials can supply important patient-reported information not captured by other ...endpoints. Both an appropriate HRQoL measure and sound methodology are required in order to draw valid inferences about treatments and HRQoL. This paper provides the current consensus of the HRQoL Outcomes Group. Particular consideration has been given to the appropriateness of measurement scales, the rationale for including specific domains as endpoints, the importance of considering baseline ceiling effects and the difficulties of data interpretation. Guidance is provided on HRQoL measurement in National and European CF clinical trials.
PDF
